AsthmaNCT01468805
Childhood Asthma Reduction Study
A study testing Cockroach mitigation/extermination in people with Asthma, run by National Institute of Environmental Health Sciences (NIEHS).
Trial summary
Background: Cockroach allergies are an important risk factor for asthma in inner-city households, especially in children. A new method for killing cockroaches may help children who live in households that have high numbers of cockroaches. Read more about this study
- Who is it for?
- Ages 5 to 14 years
- Conditions the study is for
- Asthma
- What is being tested?
- Cockroach mitigation/extermination
- Type of treatment
- Surgery or procedure
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- 4 Sep 2011to 15 Nov 2013
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 14 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- A child will be included in this study if the following criteria apply:
- (Assessed during phone screening)
- Aged 5 to 14 years of age
- Physician diagnosis of asthma for at least one year prior to prescreening
- Parent/guardian able and willing to provide consent; child able and willing to provide assent
- Primary caretaker and child are able to speak English or Spanish
Show all 14Show fewer
- Moderate to severe asthma as defined by the child experiencing one of the following:
- One overnight hospitalization for asthma within the past 6 months,
- OR
- --Two unscheduled clinic or emergency department visits for asthma within the past 12 months
- -Sleeps in the target home greater than or equal to 5 nights per week
- (Assessed at beginning of enrollment/baseline visit)
- Target home has greater than or equal to 30 cockroaches trapped in a 3 day period
- Positive ImmunoCAP Rapid test result to cockroach allergen
Who cannot join
- A child will be excluded from this study if the following criteria apply, as determined in the screening phone call and/or confirmed at the baseline visit:
- The child has other serious medical or chronic illnesses, other than asthma, such as:
- Any hematologic, metabolic/endocrine, respiratory (other than asthma), cardiac or neurologic disorder requiring daily medications;
- Any severe behavioral problem that prohibits the child or the child s caregiver from answering questions or following instructions;
- Any autoimmune disease including rheumatoid arthritis, lupus, and myositis;
- Any immune deficiency;
Show all 10Show fewer
- Any other serious medical condition such as juvenile diabetes mellitus, hypothyroidism, hyperthyroidism, cerebral palsy, hyperimmunoglobulin E syndrome, or diagnosed allergic bronchopulmonary aspergillosis.
- Plans to move within the 12 months of study enrollment
- Has no caregiver with access to a phone
- Sibling or other household member currently participating in the study.
About this study
Background:
- Cockroach allergies are an important risk factor for asthma in inner-city households, especially in children. A new method for killing cockroaches may help children who live in households that have high numbers of cockroaches. Because most public health treatments target more than just cockroaches, this method could lower the costs of treating childhood allergies and asthma by focusing on the most likely source of the allergy.
Read more
Objectives:
- To test a new cockroach-killing method designed to reduce asthma in children exposed to cockroaches.
Eligibility:
- Children 5 to 14 years of age who have moderate to severe asthma.
- Children must live in a household that has a high number of cockroaches.
Design:
- Participants will be screened with a phone call and an initial home visit.
- Study doctors will place cockroach traps, and return after 3 days to check the number of roaches caught and killed. Dust samples will be collected from the house.
- Participants will have blood and lung function tests, and will be tested for allergies (including cockroach allergies).
- Some households will be treated for cockroaches at regular intervals, or more frequently if required by the study doctors.
- Participants will have regular checkup visits in their homes at months 1, 3, 6, 9, and 12 and short phone call interviews at months 2, 4, 6, 8 and 10 to study their asthma symptoms. The home visits will also check the cockroach levels in the house.
Read the detailed description
Asthma is the most prevalent chronic childhood condition and is the most frequent cause of hospitalization among children. There are about 6.7 million children in the U.S. who currently have asthma, and nearly two of every three of these children had at least one attack in the past 12 months. Evidence suggests that exposure to cockroach allergen might be the most important risk factor for asthma in inner-city households. An environmental intervention targeting only cockroach allergen could potentially provide cost savings in a public health program over high cost multi-component interventions, if it could be shown to reduce asthma morbidity.
The primary objective of the Childhood Asthma REduction Study (CARES) is to evaluate the effectiveness of a novel cockroach eradication method, shown in prior studies to drastically decrease cockroach allergen levels, in reducing asthma morbidity in children with moderate to severe asthma who are both allergic and exposed to cockroach allergen. Additionally, the study will characterize relationships between cockroach infestation and other environmental allergen exposures, and asthma morbidity, as well as consider dynamic relationships between cockroach counts and observed allergen reductions over time; and use study data to identify mechanisms such as cleaning behaviors that may influence those relationships.
These objectives will be addressed through a prospective, randomized controlled, multi-site intervention trial in which 414 eligible children age 5 to 14 years who live in households with a confirmed trap count of 30 or more cockroaches over a 3-day period, are randomly assigned to one of two treatment groups. Treatment will be implemented at multiple intervals in the homes of children assigned to the intervention group. Children in both the intervention and control groups will receive clinical evaluations for asthma, home assessments of allergen exposures, educational materials on allergen exposures and asthma, and information on study results. Following 12-months of active data collection, the extermination treatment will be made available to the homes of children in the control group. The target sample size is 372 participants completing the study, equally divided into the two arms. Home environmental assessments following the enrollment visit will take place at enrollment, 1, 3, 6, 9, and 12 months. Clinical assessments will also be conducted in the home at enrollment and the 12-month visit. Primary outcome data will be collected during scheduled follow up phone calls every two months.
- Conditions
- Asthma
- Being tested
- Cockroach mitigation/extermination
- Keywords
- Environmental Intervention, Indoor Allergens, Cockroach, Health Disparities, Multi-Center, Asthma, Environment
- Medical subject headings
- Asthma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cockroach mitigation/exterminationProcedure or surgery
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in the mean number of maximum asthma symptom days.
Secondary outcomes (1)
Asthma-related medical care resource utilization, Lung function, Medication use, Cockroach Number and Allergen Reductions.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Nov 2011 (estimated)
- Study start4 Sep 2011
- Primary completion15 Nov 2013
- Study completion15 Nov 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AsthmaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- Sponsor type
- US National Institutes of Health
- Investigators
- Darryl C Zeldin, M.D., Principal investigator, National Institute of Environmental Health Sciences (NIEHS)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01468805
- Sponsor's protocol ID
- 110230
- Other IDs
- 11-E-0230
- Status last verified
- 15 Nov 2013
- First submitted
- 10 Sep 2011
- Last updated
- 9 Dec 2019
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Dec 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Childhood Asthma Reduction Study
- ClinicalTrials.gov ID
- NCT01468805
- Acronym / sponsor ID
- 110230
- Conditions
- Asthma
- Keywords
- Environmental Intervention, Indoor Allergens, Cockroach, Health Disparities, Multi-Center, Asthma, Environment
- Study type
- Interventional
- Recruitment status
- Withdrawn
- Enrolment
- 0 participants (actual)
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)US National Institutes of Health
- Study start
- 4 Sep 2011
- Primary completion
- 15 Nov 2013 (actual)
- Study completion
- 15 Nov 2013 (actual)
- First posted
- 10 Nov 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background:
- Cockroach allergies are an important risk factor for asthma in inner-city households, especially in children. A new method for killing cockroaches may help children who live in households that have high numbers of cockroaches. Because most public health treatments target more than just cockroaches, this method could lower the costs of treating childhood allergies and asthma by focusing on the most likely source of the allergy.
Objectives:
- To test a new cockroach-killing method designed to reduce asthma in children exposed to cockroaches.
Eligibility:
- Children 5 to 14 years of age who have moderate to severe asthma.
- Children must live in a household that has a high number of cockroaches.
Design:
- Participants will be screened with a phone call and an initial home visit.
- Study doctors will place cockroach traps, and return after 3 days to check the number of roaches caught and killed. Dust samples will be collected from the house.
- Participants will have blood and lung function tests, and will be tested for allergies (including cockroach allergies).
- Some households will be treated for cockroaches at regular intervals, or more frequently if required by the study doctors.
- Participants will have regular checkup visits in their homes at months 1, 3, 6, 9, and 12 and short phone call interviews at months 2, 4, 6, 8 and 10 to study their asthma symptoms. The home visits will also check the cockroach levels in the house.
Detailed description
Asthma is the most prevalent chronic childhood condition and is the most frequent cause of hospitalization among children. There are about 6.7 million children in the U.S. who currently have asthma, and nearly two of every three of these children had at least one attack in the past 12 months. Evidence suggests that exposure to cockroach allergen might be the most important risk factor for asthma in inner-city households. An environmental intervention targeting only cockroach allergen could potentially provide cost savings in a public health program over high cost multi-component interventions, if it could be shown to reduce asthma morbidity.
The primary objective of the Childhood Asthma REduction Study (CARES) is to evaluate the effectiveness of a novel cockroach eradication method, shown in prior studies to drastically decrease cockroach allergen levels, in reducing asthma morbidity in children with moderate to severe asthma who are both allergic and exposed to cockroach allergen. Additionally, the study will characterize relationships between cockroach infestation and other environmental allergen exposures, and asthma morbidity, as well as consider dynamic relationships between cockroach counts and observed allergen reductions over time; and use study data to identify mechanisms such as cleaning behaviors that may influence those relationships.
These objectives will be addressed through a prospective, randomized controlled, multi-site intervention trial in which 414 eligible children age 5 to 14 years who live in households with a confirmed trap count of 30 or more cockroaches over a 3-day period, are randomly assigned to one of two treatment groups. Treatment will be implemented at multiple intervals in the homes of children assigned to the intervention group. Children in both the intervention and control groups will receive clinical evaluations for asthma, home assessments of allergen exposures, educational materials on allergen exposures and asthma, and information on study results. Following 12-months of active data collection, the extermination treatment will be made available to the homes of children in the control group. The target sample size is 372 participants completing the study, equally divided into the two arms. Home environmental assessments following the enrollment visit will take place at enrollment, 1, 3, 6, 9, and 12 months. Clinical assessments will also be conducted in the home at enrollment and the 12-month visit. Primary outcome data will be collected during scheduled follow up phone calls every two months.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
Who may qualify
- Ages
- 5 to 14 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (14 listed)
- (Assessed during phone screening)
- Aged 5 to 14 years of age
- Physician diagnosis of asthma for at least one year prior to prescreening
- Parent/guardian able and willing to provide consent; child able and willing to provide assent
- Primary caretaker and child are able to speak English or Spanish
Key exclusion criteria (10 listed)
- A child will be excluded from this study if the following criteria apply, as determined in the screening phone call and/or confirmed at the baseline visit:
- The child has other serious medical or chronic illnesses, other than asthma, such as:
- Plans to move within the 12 months of study enrollment
- Has no caregiver with access to a phone
- Sibling or other household member currently participating in the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cockroach mitigation/extermination | Procedure or surgery | – |
Primary outcome
Change in the mean number of maximum asthma symptom days.
1 secondary outcome
Asthma-related medical care resource utilization, Lung function, Medication use, Cockroach Number and Allergen Reductions.
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Dec 2019.
Related trials for Asthma
Active, not recruitingPhase 1
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
Asthma
RecruitingPhase 2
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
Asthma
RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma
Asthma
Enrolling by invitationObservational study
Firefighter's Longitudinal Airway and Respiratory Exposome/Multiome Study (FLARES)
Anosmia, Chronic Obstructive Pulmonary Disease
RecruitingObservational study
Asthma and Primary Arterial Hypertension: an Inflammatory Link?
Asthma Bronchial
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Darryl C Zeldin, M.D. principal investigator
National Institute of Environmental Health Sciences (NIEHS)
Questions about this trial
What is this clinical trial studying?
A study testing Cockroach mitigation/extermination in people with Asthma, run by National Institute of Environmental Health Sciences (NIEHS).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 9 Dec 2019. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in the mean number of maximum asthma symptom days.. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Dec 2019; AzTrials last refreshed its copy on 31 Oct 2026.